Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHA:600671)
China · Delayed Price · Currency is CNY 22.52
0.00 (0.00%)
Sep 14, 2026, 3:00 PM CST
SHA:600671 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,742 | 2,108 | 1,069 | 1,420 | 1,158 | 1,094 | |
Market Cap Growth | 21.21% | 97.15% | -24.70% | 22.61% | 5.90% | 4.30% |
Enterprise Value | 2,885 | 2,298 | 1,174 | 1,451 | 1,262 | 1,178 |
Last Close Price | 22.52 | 17.31 | 8.78 | 11.66 | 9.51 | 8.98 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 200.50 | 119.62 | 70.13 | - | - | - |
PS Ratio | 13.22 | 9.96 | 4.92 | 11.66 | 10.63 | 7.44 |
PB Ratio | 27.72 | 22.43 | 12.58 | 25.38 | 254.02 | 16.94 |
P/TBV Ratio | 39.31 | 33.26 | 23.41 | 47.77 | - | 30.09 |
P/OCF Ratio | 58.41 | 178.78 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 13.90 | 10.85 | 5.40 | 11.92 | 11.59 | 8.01 |
EV/EBITDA Ratio | 75.63 | 80.60 | 28.44 | - | - | - |
EV/EBIT Ratio | 166.49 | 163.63 | 39.88 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.92 | 1.76 | 1.79 | 2.05 | 25.45 | 1.76 |
Debt / EBITDA Ratio | 4.98 | 4.29 | 3.17 | - | - | - |
Net Debt / Equity Ratio | 1.21 | 1.43 | 1.02 | 0.30 | 16.16 | 1.42 |
Net Debt / EBITDA Ratio | 3.76 | 4.70 | 2.10 | -1.47 | -2.54 | -4.67 |
Net Debt / FCF Ratio | 4.31 | -6.91 | -1.51 | -0.57 | -3.22 | -2.94 |
Asset Turnover | 0.48 | 0.48 | 0.55 | 0.38 | 0.31 | 0.35 |
Inventory Turnover | 2.38 | 2.44 | 2.45 | 2.17 | 1.88 | 1.78 |
Quick Ratio | 0.68 | 0.64 | 0.58 | 0.62 | 0.34 | 0.51 |
Current Ratio | 0.84 | 0.81 | 0.78 | 0.82 | 0.56 | 0.74 |
Return on Equity (ROE) | 5.98% | 8.05% | 31.02% | -129.89% | -211.59% | -41.52% |
Return on Assets (ROA) | 2.53% | 1.99% | 4.67% | -4.33% | -7.78% | -4.32% |
Return on Invested Capital (ROIC) | 3.72% | 4.95% | 18.13% | -29.84% | -37.48% | -16.44% |
Return on Capital Employed (ROCE) | 10.70% | 8.80% | 19.00% | -17.90% | -54.00% | -19.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.50% | 0.84% | 1.43% | -2.70% | -5.83% | -2.73% |
FCF Yield | 1.01% | -0.92% | -5.35% | -2.07% | -1.98% | -2.85% |
Payout Ratio | 48.18% | 36.87% | 56.30% | - | - | - |
Buyback Yield / Dilution | -0.03% | -0.01% | 0.01% | 0.00% | 1.92% | -1.13% |